Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.

作者: J. -F. Chiou , J. -A. Liang , W. -H. Hsu , J. -J. Wang , S. -T. Ho

DOI: 10.1007/S00408-003-1029-7

关键词: PaclitaxelP-glycoproteinAdenocarcinomaImmunohistochemistryInternal medicineBiopsyPerformance statusBiologyLung cancerChemotherapyOncology

摘要: Our aim was to compare Taxol-based chemotherapy response of non-small cell lung cancer (NSCLC) with P-glycoprotein (Pgp) or resistance protein expression (LRP). Immunohistochemical analyses were performed on multiple nonconsecutive sections the biopsy specimens detect Pgp and LPR expressions in 40 patients advanced NSCLC before chemotherapy. The evaluated by clinical radiological methods third month after completion treatment. No significant differences prognostic factors (age, sex, body weight loss, performance status, tumor size, stage, type) found between 20 good poor responses. incidence difference positive responses significant, however, LRP not. We concluded that related but not expression.

参考文章(20)
Jean-Paul Sculier, Jean Klastersky, Chemotherapy of non-small-cell lung cancer. Seminars in Oncology. ,vol. 12, pp. 38- 48 ,(1985) , 10.5555/URI:PII:0093775485901046
Shuk Han Cheng, Wing Lam, Agnes S.K. Lee, Kwok Pui Fung, Rudolf S.S. Wu, Wang Fun Fong, Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution Toxicology and Applied Pharmacology. ,vol. 164, pp. 134- 142 ,(2000) , 10.1006/TAAP.2000.8903
J van Ark-Otte, G Samelis, G Rubio, J B Lopez Saez, H M Pinedo, G Giaccone, Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncology Reports. ,vol. 5, pp. 249- 304 ,(1998) , 10.3892/OR.5.1.249
Bin Liu, Edgar D. Staren, Takeshi Iwamura, Hubert E. Appert, John M. Howard, Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. Journal of Surgical Research. ,vol. 99, pp. 179- 186 ,(2001) , 10.1006/JSRE.2001.6126
Prudence A. Francis, Mark G. Kris, James R. Rigas, Stefan C. Grant, Vincent A. Miller, Paclitaxel (Taxol) and Docetaxel (Taxotere): active chemotherapeutic agents in lung cancer Lung Cancer. ,vol. 12, ,(1995) , 10.1016/0169-5002(95)00432-Z
Miguel A. Izquierdo, Robert H. Shoemaker, Marcel J. Flens, George L. Scheffer, Lin Wu, Tanya R. Prather, Rik J. Scheper, Overlapping phenotypes of multidrug resistance among panels of human cancer‐cell lines International Journal of Cancer. ,vol. 65, pp. 230- 237 ,(1996) , 10.1002/(SICI)1097-0215(19960117)65:2<230::AID-IJC17>3.0.CO;2-H
S. B. HORWITZ, L. LOTHSTEIN, J. J. MANFREDI, W. MELLADO, J. PARNESS, S. N. ROY, P. B. SCHIFF, L. SORBARA, R. ZEHEB, Taxol: mechanisms of action and resistance. Annals of the New York Academy of Sciences. ,vol. 466, pp. 733- 744 ,(1986) , 10.1111/J.1749-6632.1986.TB38455.X
D. P Carbone, J. D Minna, Chemotherapy for non-small cell lung cancer BMJ. ,vol. 311, pp. 889- 890 ,(1995) , 10.1136/BMJ.311.7010.889
Martin M. Oken, Richard H. Creech, Douglass C. Tormey, John Horton, Thomas E. Davis, Eleanor T. McFadden, Paul P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology. ,vol. 5, pp. 649- 655 ,(1982) , 10.1097/00000421-198212000-00014